• STJ70153 staining (0. 5µg/ml) of Human Placenta lysate (RIPA buffer, 35µg total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescence.

Anti-AIBZIP/CREB3L4 antibody (C-Term) (STJ70153)

SKU:
STJ70153-100

Shipping:
Free Shipping
Current Stock:
Host: Goat
Applications: Pep-ELISA/WB/IHC
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Goat polyclonal antibody anti-AIBZIP/CREB3L4 (C-Term) is suitable for use in ELISA, Western Blot and Immunohistochemistry research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA
Purification: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Concentration: 0.5 mg/mL
Dilution Range: WB-Recommended for use at 0.5-2µg/ml
IHC-Recommended concentration, 2-4µg/ml
ELISA-antibody detection limit dilution 1:32000.
Storage Instruction: Store at-20°C on receipt and minimise freeze-thaw cycles.
Gene Symbol: CREB3L4
Gene ID: 148327
Uniprot ID: CR3L4_HUMAN
Immunogen Region: C-Term
Accession Number: NP_570968.1; NP_001242909.1
Specificity: This antibody is expected to recognize both reported isoforms (NP_570968.1; NP_001242909.1). Reported variants represent identical protein: NP_001242908.1, NP_570968.1, NP_001242907.1 Reported variants represent identical protein: NP_001242909.1, NP_
Immunogen Sequence: PSGRIRSVLHADEM
Post Translational Modifications N-glycosylated in the C-terminal region. Controlled by regulated intramembrane proteolysis (RIP). Following ER stress a fragment containing the cytoplasmic transcription factor domain is released by proteolysis. The cleavage seems to be performed sequentially by site-1 and site-2 proteases (PS1 and PS2). PS1 cleavage may be suppressed by a determinant in the C-terminal region.
Function Transcriptional activator that may play a role in the unfolded protein response. Binds to the UPR element (UPRE) but not to CRE element. Preferentially binds DNA with to the consensus sequence 5'-TGTACGTGAGT-3' and has transcriptional activation activity from UPRE. Binds to NF-kappa-B site and has transcriptional activation activity from NF-kappa-B-containing regulatory elements.
Protein Name Cyclic Amp-Responsive Element-Binding Protein 3-Like Protein 4
Camp-Responsive Element-Binding Protein 3-Like Protein 4
Androgen-Induced Basic Leucine Zipper Protein
Aibzip
Attaching To Cre-Like 1
Atce1
Cyclic Amp-Responsive Element-Binding Protein 4
Creb-4
Camp-Responsive Element-Binding Protein 4
Transcript Induced In Spermiogenesis Protein 40
Tisp40
Hjal Cleaved Into - Processed Cyclic Amp-Responsive Element-Binding Protein 3-Like Protein 4
Database Links Reactome: R-HSA-8874211
Cellular Localisation Endoplasmic Reticulum Membrane
Single-Pass Type Ii Membrane Protein
Golgi Apparatus Membrane
May Also Be Located In Golgi Apparatus
Processed Cyclic Amp-Responsive Element-Binding Protein 3-Like Protein 4: Nucleus
Under Er Stress The Cleaved N-Terminal Cytoplasmic Domain Translocates Into The Nucleus
Alternative Antibody Names Anti-Cyclic Amp-Responsive Element-Binding Protein 3-Like Protein 4 antibody
Anti-Camp-Responsive Element-Binding Protein 3-Like Protein 4 antibody
Anti-Androgen-Induced Basic Leucine Zipper Protein antibody
Anti-Aibzip antibody
Anti-Attaching To Cre-Like 1 antibody
Anti-Atce1 antibody
Anti-Cyclic Amp-Responsive Element-Binding Protein 4 antibody
Anti-Creb-4 antibody
Anti-Camp-Responsive Element-Binding Protein 4 antibody
Anti-Transcript Induced In Spermiogenesis Protein 40 antibody
Anti-Tisp40 antibody
Anti-Hjal Cleaved Into - Processed Cyclic Amp-Responsive Element-Binding Protein 3-Like Protein 4 antibody
Anti-CREB3L4 antibody
Anti-AIBZIP antibody
Anti-CREB4 antibody
Anti-JAL antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance